Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY

17 Aug 2023 08:58 CEST

HBC Immunology LLC ("HBCI" or the "Company"), a majority owned subsidiary of
Hofseth BioCare ASA ("HBC"), has successfully completed the required minimum
seed capital financing of approx. USD 900,000 from external investors at a
company valuation of USD 20 million to commence preclinical animal trials with
their patented peptides, FT-002 and FT-005. These are analogs of peptides
discovered by HBC in ProGo® Bioactive Peptides which modulate iron metabolism
and have Qualified Health claims granted for this mode of action, verifying
their safety and efficacy. HBCI may increase this round of seed capital to the
end of October 2023.

HBCI is focused on the discovery and development of peptides that normalize
tumor micro-environments, resulting in the improved performance of
immunotherapies and chemotherapies. The first targeted indication is advanced
prostate cancer with the aim to move into earlier stages of the disease and
ultimately to both improve patient quality of life and survival. Other potential
cancer indications with on-going in vitro work, include breast and ovarian
cancer.

HBCI's CEO Dr. Bomi Framroze says: "HBCI is at the forefront of research in
using peptides to modulate gene expression. Our first therapeutic target is
resistant CRPC (Castration-resistant prostate cancer). We hope to reinvigorate
the sensitivity of these tumors to standard AR inhibitors via modulation of the
FTH1 gene within the tumor micro environment."

The objective of this round's use of proceeds is to demonstrate the bioactivity
of the lead peptides in animal xenograft models of prostate cancer. This seed
capital is expected to fund HBCI to a decision to open a US FDA IND by the end
of 2024.

For further information, please contact:
Dr. Crawford Currie, MD
Head of Medical R&D at HBC, CMO at HBCI
Mob: +44 7968195497
E-mail: cc@hofsethbiocare.no

About HBC:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using a special formula of
soluble protein hydrolysate (SPH also known as ProGo®) as a Medical Food to help
treat IBD, and for Iron Deficiency Anemia.

The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. HBC's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto. HBC is
listed on Oslo Børs with ticker "HBC".

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading
Act.

More information:
Access the news on Oslo Bors NewsWeb site